top of page
MENU
MENU
News Release
PURMX Therapeutics Selected as an Awardee of the Japan Smart Healthy Aging QuickFire Challenge
PURMX Therapeutics, Inc. (Headquarters: Hiroshima-city, Hiroshima; President & CEO: Hidetoshi Tahara) is pleased to announce that it has...
Sep 8
PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA
PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced...
May 9
PURMX Therapeutics Initiates Phase I Clinical Trial of MIRX002, a Novel MicroRNA-Based Anticancer Drug, for Head and Neck Cancer
PURMX Therapeutics, Inc. (hereinafter referred to as “PURMX”) (Head Office: 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima...
Mar 31
bottom of page